Mosaic (MOS) Q4 2025: $960M Working Capital Drain Signals Cash Flow Reset for 2026

2026-02-25 | By EarningsIQ Research

Mosaic’s fourth quarter exposed acute working capital and margin pressures, but operational resets and global market tailwinds position the company for a cash flow rebound in 2026. U.S. phosphate demand weakness and volatile sulfur costs compressed margins, while Brazil’s credit crunch forced volume conservatism. With cost discipline, asset divestitures, and a surging Biosciences platform, Mosaic is pivoting toward a leaner, more resilient model as market conditions stabilize.

Summary

• Cash Flow Recovery Hinges on Working Capital Release: Mosaic expects $300–500 million in working capital release to drive cash flow uplift in 2026.
• Production and Cost Structure Reset Underway: U.S. phosphate and potash operations are targeting higher utilization and sub-$100/ton conversion costs.
• Biosciences Emerges as a Scalable Growth Platform: Doubling net sales and high-margin expansion signal a strategic shift beyond commodity fertilizers.

Performance Analysis

Mosaic’s Q4 2025 was marked by a pronounced drop in U.S. phosphate demand, driven by affordability challenges and delayed government payments, resulting in inventory builds and a $960 million working capital drag for the year. This dynamic, coupled with a sharp spike in sulfur prices, significantly compressed phosphate margins and led to the idling of lower-margin Brazilian operations (Araxá and Fospar). Potash production, by contrast, remained stable, with international sales volumes setting a record, demonstrating the company’s ability to capture share even as overall North American shipments fell.

Despite these headwinds, Mosaic made tangible progress on cost reduction, achieving its $150 million savings target ahead of schedule and lowering phosphate conversion costs to $112/ton in Q4, a $20 improvement from earlier highs. The company’s Brazilian operations delivered near-record rock output and eliminated high-cost imported rock, while the Mosaic Biosciences business doubled net sales to $68 million and maintained gross margins in the 40s, highlighting the potential for margin expansion as new products scale.

• Margin Compression: Sulfur price inflation and weak U.S. phosphate demand drove stripping margins down, pressuring Q1 2026 EBITDA by $250 million versus prior year.
• Inventory Overhang: Excess phosphate inventory and raw materials represent $140 million in potential working capital release as demand recovers.
• Operational Flexibility: Production curtailments in Brazil and asset divestitures are refocusing resources on higher-return segments and geographies.

The company’s ability to normalize working capital and further optimize fixed cost absorption in 2026 will be critical for restoring free cash flow and supporting capital allocation priorities.

Executive Commentary

Strategic Positioning

1. Operational Stabilization in Phosphate and Potash

Mosaic’s 2025 priority was restoring production stability and cost normalization in its U.S. phosphate business, with P2O5 output and fertilizer production improving quarter over quarter. The company expects to produce at least 7 million tons of phosphate and 9 million tons of potash in 2026, with high operating rates following asset turnarounds and reliability investments.

2. Aggressive Cost Discipline and Asset Rationalization

Cost management initiatives included mine optimization, supplier consolidation, and idling of low-margin Brazilian assets. The company achieved structural cost improvements, notably in Brazil, and accelerated non-core asset divestitures (Patos de Minas, Tecori, and pending Carlsbad sale), generating $170 million in proceeds and reducing future capital requirements.

3. Pivot to High-Margin, Scalable Biosciences

Mosaic Biosciences, the company’s biologicals and specialty crop nutrition business, doubled net sales and expanded into 16 countries, with gross margins in the 40s and prospects for further expansion as 8–10 new products launch in 2026. This segment is positioned as a key driver of future margin accretion and portfolio diversification.

4. Capital Allocation Focused on Debt Reduction and Shareholder Returns

With free cash flow generation expected to rebound, Mosaic intends to prioritize debt reduction in the near term, paving the way for extraordinary shareholder returns once balance sheet flexibility is restored. CapEx will remain elevated in 2026 due to a confluence of required waste disposal projects, but is projected to trend down to $1 billion by 2030.

5. Market Access and Geographic Diversification

Expanded blending capacity and logistics in Brazil, alongside a flexible global distribution platform, allow Mosaic to pivot product mix and volumes to higher-margin international markets as U.S. demand fluctuates and China maintains export restrictions.

Key Considerations

Mosaic’s quarter was defined by acute margin and working capital pressure, offset by progress in cost structure, asset optimization, and the emergence of high-margin growth platforms. The company’s ability to release working capital, manage sulfur price volatility, and execute on production ramp-ups will determine the pace of cash flow normalization and shareholder returns in 2026.

Key Considerations:

• Cash Conversion Reset: The company’s EBITDA-to-cash flow conversion rate dropped to the mid-30s in 2025, but is expected to rebound toward 70% as inventory unwinds and demand recovers.
• Sulfur Price Volatility: Elevated sulfur costs are a major variable for phosphate margins, with every $10/ton increase adding $10 million in quarterly expense.
• Brazilian Market Risk: Credit constraints and market consolidation in Brazil cap volume growth, but position Mosaic for upside as the market stabilizes.
• Flexible Production Strategy: The ability to shift phosphate volumes between North America and international markets based on relative margin opportunity is a structural advantage.
• Biosciences Margin Expansion: Continued product launches and geographic expansion in Mosaic Biosciences offer a scalable, high-margin growth lever.

Risks

Persistent sulfur and ammonia price inflation, weak U.S. farmer affordability, and ongoing credit constraints in Brazil present material risks to margin recovery and volume growth. Working capital normalization is vulnerable to slower-than-anticipated demand recovery, while production ramp-ups depend on successful asset turnarounds and operational execution. Regulatory uncertainty, especially around U.S. countervailing duties and environmental liabilities, could further impact costs and market access.

Forward Outlook

For Q1 2026, Mosaic guided to:

• Phosphate production of at least 7 million tons for the full year, with near-term headwinds from sulfur cost inflation.
• Potash production of approximately 9 million tons, matching 2025 levels.

For full-year 2026, management did not provide explicit volume guidance for Mosaic Fertilizantes due to Brazil market uncertainty, but expects:

• $300–500 million in working capital release, driving improved cash flow.
• CapEx around $1.5 billion, with a downward trend projected through 2030.

Management highlighted that margin recovery, working capital normalization, and cost absorption from higher production rates will be the primary drivers of financial improvement. Sulfur and ammonia price trends, as well as global demand signals, are key variables for the year.

• Working capital release is expected to be most pronounced in Q2 and Q3 as inventories are drawn down.
• International phosphate sales may increase if Chinese export restrictions persist.

Takeaways

Mosaic’s Q4 2025 revealed the fragility of cash flow in the face of commodity price and demand shocks, but also demonstrated management’s ability to respond with aggressive cost actions, asset rationalization, and operational resets. The pivot toward high-margin Biosciences and flexible market access positions the company for improved resilience and upside as ag fundamentals recover.

• Cash Flow Inflection: 2026 will be a reset year, with working capital release and operational leverage key to restoring free cash flow and enabling debt reduction or shareholder returns.
• Production and Margin Leverage: Achieving higher utilization and sub-$100/ton phosphate conversion costs are central to margin recovery and capital efficiency.
• Strategic Optionality: Asset divestitures, disciplined capital allocation, and Biosciences growth provide Mosaic with levers to navigate market volatility and capture emerging opportunities.

Conclusion

Mosaic enters 2026 with a leaner, more disciplined operating posture, having weathered a challenging quarter marked by margin compression and working capital strain. Execution on cost, production, and capital discipline will be decisive, while the scaling of Biosciences and international market access offer durable upside as macro conditions improve.

Industry Read-Through

Mosaic’s experience underscores the volatility facing global fertilizer producers, with input cost inflation and working capital swings amplifying cash flow risk. Brazil’s credit crunch and U.S. farmer affordability issues are sector-wide headwinds, likely to pressure competitors with less operational flexibility or geographic reach. The pivot toward biologicals and specialty nutrition reflects a broader industry shift toward higher-margin, less cyclical growth platforms. Expect continued asset rationalization, cost focus, and capital discipline across the fertilizer sector as producers adapt to a more volatile, supply-constrained global market.

MOS Materials Fertilizer Agtech Biosciences Working Capital Brazil Cost Reduction